HRP20191835T1 - Protutijela anti-il-36r - Google Patents
Protutijela anti-il-36r Download PDFInfo
- Publication number
- HRP20191835T1 HRP20191835T1 HRP20191835TT HRP20191835T HRP20191835T1 HR P20191835 T1 HRP20191835 T1 HR P20191835T1 HR P20191835T T HRP20191835T T HR P20191835TT HR P20191835 T HRP20191835 T HR P20191835T HR P20191835 T1 HRP20191835 T1 HR P20191835T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (23)
1. Protutijelo anti-IL-36R ili njegov fragment koji veže antigen, naznačeno time, da obuhvaća:
a) varijabilno područje lakog lanca koje obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 80; i
b) varijabilno područje teškog lanca koje obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 87, SEQ ID NO: 88 ili SEQ ID NO:89.
2. Protutijelo anti-IL-36R prema patentnom zahtjevu 1, naznačeno time, da protutijelo obuhvaća laki lanac koji obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 118 i teški lanac koji obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 125.
3. Protutijelo anti-IL-36R prema patentnom zahtjevu 1, naznačeno time, da protutijelo obuhvaća laki lanac koji obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 118 i teški lanac koji obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 126.
4. Protutijelo anti-IL-36R prema patentnom zahtjevu 1, naznačeno time, da protutijelo obuhvaća laki lanac koji obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 118 i teški lanac koji obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 127.
5. Farmaceutski pripravak, naznačen time, da obuhvaća protutijelo ili njegov fragment koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 4 i farmaceutski prihvatljiv nosač.
6. Protutijelo ili njegov fragment koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačeni time, da se upotrebljavaju u medicini.
7. Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 6, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja upalne bolesti, autoimune bolesti, respiratorne bolesti, metaboličkog poremećaja, upalnog epitelno posredovanog poremećaja, fibroze ili raka.
8. Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 6 ili 7, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja psorijaze, upalne bolesti crijeva, psorijatičkog artritisa, multiple skleroze, reumatoidnog artritisa, KOPB-a, kronične astme ili ankiloznog spondilitisa.
9. Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 8, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja upalne bolesti crijeva.
10. Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 9, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja Crohnove bolesti.
11. Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 9, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja bolesti ulcerativnog kolitisa.
12. Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 8, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja palmoplantarne pustuloze.
13. Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 8, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja generalizirane pustularne psorijaze.
14. Izolirani polinukleotid, naznačen time, da obuhvaća sekvencu koja kodira protutijelo anti-IL-36R ili njegov fragment koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 4, poželjno DNK ili RNK sekvencu.
15. Izolirani polinukleotid prema patentnom zahtjevu 14, naznačen time, da on kodira:
(a) varijabilno područje lakog lanca koje obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 80; i varijabilno područje teškog lanca koje obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 87, SEQ ID NO: 88 ili SEQ ID NO:89; ili
(b) laki lanac i teški lanac koji obuhvaćaju odgovarajuće aminokiselinske sekvence iz SEQ ID NO:118 odnosno SEQ ID NO: 125; SEQ ID NO:118 odnosno SEQ ID NO: 126; ili SEQ ID NO:118 odnosno SEQ ID NO: 127.
16. Vektor, naznačen time, da obuhvaća polinukleotid u skladu s patentnim zahtjevom 14 ili 15, poželjno vektor ekspresije, još poželjnije vektor koji obuhvaća polinukleotid u skladu s izumom u funkcionalnoj povezanosti s kontrolnom sekvencom ekspresije.
17. Stanica domaćina, naznačena time, da obuhvaća polinukleotid u skladu s patentnim zahtjevom 14 ili 15, i/ili vektor u skladu s patentnim zahtjevom 16.
18. Postupak proizvodnje protutijela anti-IL-36R ili njegovog fragmenta koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da obuhvaća uporabu polinukleotida u skladu s patentnim zahtjevom 14 ili 15, i/ili vektora u skladu s patentnim zahtjevom 16 i/ili stanice domaćina u skladu s patentnim zahtjevom 17.
19. Postupak u skladu s patentnim zahtjevom 18, naznačen time, da obuhvaća korake (a) kultiviranja stanice domaćina pod uvjetima koji dopuštaju ekspresiju protutijela anti-IL-36R ili njegovog fragmenta koji veže antigen, i (b) dobivanje protutijela anti-IL-36R ili njegovog fragmenta koji veže antigen.
20. Dijagnostička garnitura, naznačena time, da obuhvaća protutijelo anti-IL-36R ili njegov fragment koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
21. Dijagnostička garnitura prema patentnom zahtjevu 20, naznačena time, da se upotrebljava u postupku in vivo dijagnoze upalne bolesti, autoimune bolesti, respiratorne bolesti, metaboličkog poremećaja, upalnog epitelno posredovanog poremećaja, fibroze, raka, psorijaze, upalne bolesti crijeva, psorijatičkog artritisa, multiple skleroze, reumatoidnog artritisa, KOPB-a, kronične astme, ankiloznog spondilitisa, Crohnove bolesti, ili bolesti ulcerativnog kolitisa.
22. Dijagnostički postupak ex vivo, naznačen time, da obuhvaća uporabu protutijela anti-IL-36R ili njegovog fragmenta koji veže antigen u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
23. Dijagnostički postupak ex vivo u skladu s patentnim zahtjevom 22, naznačen time, da služi za dijagnozu upalne bolesti, autoimune bolesti, respiratorne bolesti, metaboličkog poremećaja, upalnog epitelno posredovanog poremećaja, fibroze, raka, psorijaze, upalne bolesti crijeva, psorijatičkog artritisa, multiple skleroze, reumatoidnog artritisa, KOPB-a, kronične astme, ankiloznog spondilitisa, Crohnove bolesti, ili bolesti ulcerativnog kolitisa.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161560554P | 2011-11-16 | 2011-11-16 | |
| US201261644111P | 2012-05-08 | 2012-05-08 | |
| US201261713713P | 2012-10-15 | 2012-10-15 | |
| PCT/US2012/064933 WO2013074569A1 (en) | 2011-11-16 | 2012-11-14 | Anti il-36r antibodies |
| EP12788410.4A EP2780373B1 (en) | 2011-11-16 | 2012-11-14 | Anti il-36r antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191835T1 true HRP20191835T1 (hr) | 2019-12-27 |
Family
ID=47215803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191835TT HRP20191835T1 (hr) | 2011-11-16 | 2019-10-10 | Protutijela anti-il-36r |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US9023995B2 (hr) |
| EP (2) | EP2780373B1 (hr) |
| JP (3) | JP6289375B2 (hr) |
| KR (3) | KR102159109B1 (hr) |
| CN (5) | CN118496365A (hr) |
| AP (1) | AP2014007571A0 (hr) |
| AR (1) | AR089178A1 (hr) |
| AU (1) | AU2012339734B2 (hr) |
| BR (1) | BR112014011594B1 (hr) |
| CA (1) | CA2852994C (hr) |
| CL (1) | CL2014001123A1 (hr) |
| CO (1) | CO7020871A2 (hr) |
| CY (2) | CY1122278T1 (hr) |
| DK (1) | DK2780373T3 (hr) |
| EA (1) | EA031948B1 (hr) |
| EC (1) | ECSP14004976A (hr) |
| ES (1) | ES2755732T3 (hr) |
| FI (1) | FIC20230020I1 (hr) |
| FR (1) | FR23C1023I2 (hr) |
| HR (1) | HRP20191835T1 (hr) |
| HU (2) | HUE047437T2 (hr) |
| IL (2) | IL232100B (hr) |
| LT (2) | LT2780373T (hr) |
| MX (1) | MX347164B (hr) |
| MY (1) | MY195289A (hr) |
| NL (1) | NL301233I2 (hr) |
| NO (2) | NO2023024I1 (hr) |
| PE (1) | PE20142041A1 (hr) |
| PH (1) | PH12014501108A1 (hr) |
| PL (1) | PL2780373T3 (hr) |
| PT (1) | PT2780373T (hr) |
| RS (1) | RS59248B1 (hr) |
| SG (1) | SG11201402283PA (hr) |
| SI (1) | SI2780373T1 (hr) |
| TW (1) | TWI573804B (hr) |
| UA (1) | UA115540C2 (hr) |
| UY (1) | UY34456A (hr) |
| WO (1) | WO2013074569A1 (hr) |
| ZA (1) | ZA201402491B (hr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2663579T (pt) | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| US9023995B2 (en) | 2011-11-16 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Anti IL-36R antibodies |
| EP3093294A1 (en) | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Dll3 modulators and methods of use |
| ME03558B (me) * | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| RU2582569C2 (ru) * | 2014-07-24 | 2016-04-27 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом |
| CN107847589B (zh) | 2015-04-01 | 2022-03-29 | 安奈普泰斯生物有限公司 | 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体 |
| MX2017013080A (es) | 2015-04-15 | 2018-02-09 | Anaptysbio Inc | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). |
| WO2016201282A2 (en) * | 2015-06-12 | 2016-12-15 | Ludwig Institute For Cancer Research Ltd | TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| JP6654773B2 (ja) * | 2015-12-25 | 2020-02-26 | 国立大学法人名古屋大学 | インターロイキン３６受容体アンタゴニスト欠損症の治療薬 |
| AU2017354071A1 (en) | 2016-11-01 | 2019-05-23 | Anaptysbio, Inc. | Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) |
| TWI841209B (zh) | 2017-01-09 | 2024-05-01 | 美商提薩羅有限公司 | 用抗tim-3抗體治療癌症之方法 |
| US20180273627A1 (en) * | 2017-03-27 | 2018-09-27 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
| WO2019136370A2 (en) * | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2 |
| JP7404256B2 (ja) * | 2018-03-14 | 2023-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 |
| EP3765515A2 (en) * | 2018-03-14 | 2021-01-20 | Boehringer Ingelheim International GmbH | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| AU2019308205A1 (en) * | 2018-07-16 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of DITRA disease and uses thereof |
| MX2021000566A (es) * | 2018-07-16 | 2021-06-23 | Regeneron Pharma | Anticuerpos anti-il36r. |
| JP2022532812A (ja) | 2018-08-16 | 2022-07-20 | カンタージア アクチエボラーグ | 抗ｉｌ１ｒａｐ抗体組成物 |
| CA3114295A1 (en) * | 2018-09-28 | 2020-04-02 | Kyowa Kirin Co., Ltd. | Il-36 antibodies and uses thereof |
| US11884719B2 (en) | 2018-12-21 | 2024-01-30 | 23Andme, Inc. | Anti-IL-36 antibodies and methods of use thereof |
| CN113301955A (zh) | 2018-12-27 | 2021-08-24 | 勃林格殷格翰国际有限公司 | 治疗掌跖脓疱症的抗il-36r抗体 |
| BR112021016198A2 (pt) | 2019-03-08 | 2021-11-03 | Boehringer Ingelheim Int | Formulações de anticorpo anti-il-36r |
| WO2021112196A1 (ja) * | 2019-12-05 | 2021-06-10 | 学校法人東京薬科大学 | 筋組織の減少を抑制するための組成物 |
| AR120913A1 (es) * | 2019-12-27 | 2022-03-30 | Teijin Pharma Ltd | Anticuerpo que inhibe específicamente la señalización de il-36r |
| WO2021236496A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for the treatment of atopic dermatitis |
| MX2023000763A (es) | 2020-07-17 | 2023-02-13 | Boehringer Ingelheim Int | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas. |
| WO2022026829A1 (en) | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| CN116406295A (zh) * | 2020-07-30 | 2023-07-07 | 安奈普泰斯生物有限公司 | 针对鱼鳞病的抗白介素36受体（il-36r）疗法 |
| MX2023003723A (es) | 2020-09-30 | 2023-04-24 | Boehringer Ingelheim Int | Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico. |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| WO2022127842A1 (zh) | 2020-12-17 | 2022-06-23 | 上海华奥泰生物药业股份有限公司 | 靶向il-17a和il-36r的双特异性抗体及其应用 |
| WO2022150644A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for acne |
| WO2022150642A1 (en) | 2021-01-08 | 2022-07-14 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa |
| WO2022166977A1 (zh) * | 2021-02-08 | 2022-08-11 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
| WO2022187434A1 (en) | 2021-03-04 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Methods for the treatment of gpp |
| JP2024512384A (ja) | 2021-03-12 | 2024-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 汎発型膿疱性乾癬における抗ｉｌ－３６ｒ抗体による処置に関連したバイオマーカー |
| EP4334356A1 (en) * | 2021-05-03 | 2024-03-13 | Boehringer Ingelheim International Gmbh | Method for producing spesolimab |
| TW202317626A (zh) * | 2021-06-18 | 2023-05-01 | 大陸商正大天晴藥業集團股份有限公司 | 抗il-36r抗體及其用途 |
| WO2023285362A1 (en) | 2021-07-12 | 2023-01-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
| US20230049147A1 (en) | 2021-08-13 | 2023-02-16 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for the treatment of a fibrotic condition |
| CN118302824A (zh) | 2021-09-28 | 2024-07-05 | 柏林格英格翰国际有限公司 | 用于评估具有可见皮肤表现的嗜中性皮肤病的严重性的系统和方法 |
| EP4259657A4 (en) | 2021-10-28 | 2024-07-03 | Abbvie Inc. | ANTI-AMYLOID-BETA ANTIBODIES AND METHODS OF USE THEREOF |
| CN115724975A (zh) * | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
| US20240301074A1 (en) | 2023-03-09 | 2024-09-12 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for the treatment of hidradentitis suppurativa (hs) |
| WO2024251927A2 (en) | 2023-06-09 | 2024-12-12 | Boehringer Ingelheim International Gmbh | Methods for the treatment and prevention of gpp |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| EP0656789B1 (en) | 1992-08-21 | 1997-12-17 | Genentech, Inc. | Method for treating a lfa-1-mediated disorder |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US6416973B1 (en) | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
| ATE523593T1 (de) | 1997-08-01 | 2011-09-15 | Schering Corp | Membranproteine aus säugetierzellen und verwandte reagentien |
| PT2857516T (pt) * | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| EP1627927A3 (en) * | 2001-03-01 | 2006-06-07 | Epigenomics AG | Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA |
| EP1556403A4 (en) * | 2002-10-03 | 2006-06-28 | Large Scale Biology Corp | ENGINEERING MULTIMERIC PROTEINS |
| SG2014010029A (en) * | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| CA2662549C (en) | 2006-09-08 | 2014-10-28 | Amgen Inc. | Il-1 family variants |
| EP2152750A1 (en) | 2007-04-23 | 2010-02-17 | Schering Corporation | Anti-mdl-1 antibodies |
| WO2009006112A1 (en) | 2007-06-29 | 2009-01-08 | Schering Corporation | Mdl-1 uses |
| RU2011105466A (ru) * | 2008-08-28 | 2012-10-10 | ВАЙЕТ ЭлЭлСи (US) | Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях |
| US9023995B2 (en) | 2011-11-16 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Anti IL-36R antibodies |
| MX2017013080A (es) | 2015-04-15 | 2018-02-09 | Anaptysbio Inc | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). |
-
2012
- 2012-11-14 US US13/676,511 patent/US9023995B2/en active Active
- 2012-11-14 JP JP2014542388A patent/JP6289375B2/ja active Active
- 2012-11-14 PE PE2014000705A patent/PE20142041A1/es active IP Right Grant
- 2012-11-14 AP AP2014007571A patent/AP2014007571A0/xx unknown
- 2012-11-14 CN CN202410673612.0A patent/CN118496365A/zh active Pending
- 2012-11-14 CA CA2852994A patent/CA2852994C/en active Active
- 2012-11-14 EA EA201400579A patent/EA031948B1/ru not_active IP Right Cessation
- 2012-11-14 LT LTEP12788410.4T patent/LT2780373T/lt unknown
- 2012-11-14 BR BR112014011594-0A patent/BR112014011594B1/pt active IP Right Grant
- 2012-11-14 SI SI201231692T patent/SI2780373T1/sl unknown
- 2012-11-14 CN CN201280054425.XA patent/CN104080808B/zh active Active
- 2012-11-14 HU HUE12788410A patent/HUE047437T2/hu unknown
- 2012-11-14 SG SG11201402283PA patent/SG11201402283PA/en unknown
- 2012-11-14 UA UAA201406586A patent/UA115540C2/uk unknown
- 2012-11-14 PT PT127884104T patent/PT2780373T/pt unknown
- 2012-11-14 CN CN202011390234.3A patent/CN112812183B/zh active Active
- 2012-11-14 AU AU2012339734A patent/AU2012339734B2/en active Active
- 2012-11-14 CN CN202410673234.6A patent/CN118515766A/zh active Pending
- 2012-11-14 WO PCT/US2012/064933 patent/WO2013074569A1/en active Application Filing
- 2012-11-14 RS RSP20191179 patent/RS59248B1/sr unknown
- 2012-11-14 ES ES12788410T patent/ES2755732T3/es active Active
- 2012-11-14 KR KR1020197030980A patent/KR102159109B1/ko active Active
- 2012-11-14 MX MX2014005759A patent/MX347164B/es active IP Right Grant
- 2012-11-14 EP EP12788410.4A patent/EP2780373B1/en active Active
- 2012-11-14 CN CN201610916419.0A patent/CN107007833B/zh active Active
- 2012-11-14 MY MYPI2019000058A patent/MY195289A/en unknown
- 2012-11-14 EP EP19169065.0A patent/EP3536710A1/en active Pending
- 2012-11-14 DK DK12788410T patent/DK2780373T3/da active
- 2012-11-14 KR KR1020147013267A patent/KR102038310B1/ko active Active
- 2012-11-14 KR KR1020207026736A patent/KR20200110476A/ko not_active Ceased
- 2012-11-14 PL PL12788410T patent/PL2780373T3/pl unknown
- 2012-11-15 AR ARP120104313A patent/AR089178A1/es active IP Right Grant
- 2012-11-15 TW TW101142698A patent/TWI573804B/zh active
- 2012-11-16 UY UY0001034456A patent/UY34456A/es active IP Right Grant
-
2014
- 2014-04-04 ZA ZA2014/02491A patent/ZA201402491B/en unknown
- 2014-04-13 IL IL232100A patent/IL232100B/en active IP Right Grant
- 2014-04-29 CL CL2014001123A patent/CL2014001123A1/es unknown
- 2014-05-14 CO CO14103887A patent/CO7020871A2/es unknown
- 2014-05-16 PH PH12014501108A patent/PH12014501108A1/en unknown
- 2014-06-13 EC ECIEPI20144976A patent/ECSP14004976A/es unknown
-
2015
- 2015-04-01 US US14/676,365 patent/US10550189B2/en active Active
-
2018
- 2018-02-06 JP JP2018019080A patent/JP6719490B2/ja active Active
-
2019
- 2019-10-10 HR HRP20191835TT patent/HRP20191835T1/hr unknown
- 2019-11-12 CY CY20191101185T patent/CY1122278T1/el unknown
- 2019-12-17 US US16/717,413 patent/US20200231684A1/en not_active Abandoned
-
2020
- 2020-01-14 IL IL272035A patent/IL272035A/en unknown
- 2020-06-16 JP JP2020103873A patent/JP2020156506A/ja active Pending
-
2023
- 2023-05-23 CY CY2023014C patent/CY2023014I1/el unknown
- 2023-05-26 LT LTPA2023518C patent/LTPA2023518I1/lt unknown
- 2023-05-30 NO NO2023024C patent/NO2023024I1/no unknown
- 2023-05-31 FR FR23C1023C patent/FR23C1023I2/fr active Active
- 2023-05-31 NL NL301233C patent/NL301233I2/nl unknown
- 2023-06-01 FI FIC20230020C patent/FIC20230020I1/fi unknown
- 2023-06-05 HU HUS2300021C patent/HUS2300021I1/hu unknown
-
2024
- 2024-08-27 US US18/815,907 patent/US20240409648A1/en active Pending
-
2025
- 2025-01-03 NO NO2025001C patent/NO2025001I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191835T1 (hr) | Protutijela anti-il-36r | |
| Shirakawa et al. | Osteopontin in cardiovascular diseases | |
| HRP20161141T1 (hr) | Anti-il-23 protutijela | |
| Tzarum et al. | Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies | |
| Su et al. | Molecular mechanism and treatment of viral hepatitis-related liver fibrosis | |
| Malenica et al. | Molecular and immunological characterization of biliary tract cancers: a paradigm shift towards a personalized medicine | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20201633T1 (hr) | Protutijela koja se vežu na il-23 | |
| HRP20240413T1 (hr) | Antitijela za neutralizaciju poliomavirusa | |
| Immanuel et al. | Vascular inflammatory diseases and endothelial phenotypes | |
| JP2017163973A5 (hr) | ||
| Graham et al. | Mesenchymal stromal cells: emerging roles in bone metastasis | |
| JP2012012402A5 (hr) | ||
| JP2017029157A5 (hr) | ||
| HRP20210123T1 (hr) | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti | |
| HRP20210120T1 (hr) | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti | |
| JP2013507970A5 (hr) | ||
| Rolih et al. | Development of a vlp-based vaccine displaying an XCT extracellular domain for the treatment of metastatic breast cancer | |
| JP2013539962A5 (hr) | ||
| Yin et al. | Inhibition of autophagy promotes the elimination of liver cancer stem cells by CD133 aptamer-targeted delivery of doxorubicin | |
| Bubela et al. | Value-engineered translation for regenerative medicine: meeting the needs of health systems | |
| Chavda et al. | The vaccine world of COVID-19: India’s Contribution | |
| Hajeri et al. | Oncolytic adenoviruses: strategies for improved targeting and specificity | |
| HRP20200058T1 (hr) | Humana anti-il-32 protutijela | |
| Patel et al. | Hepatocellular carcinoma—the influence of immunoanatomy and the role of immunotherapy |